Chlormadinone

BRAND NAMES

Chlormadinone is marketed under several brand names worldwide, often in combination with estrogen for contraceptive use or as a single agent for hormonal therapy. Some common brand names include:

• Belara – combined oral contraceptive 

• Prostal – used for benign prostatic hyperplasia 

• Chlormadinone Acetate – generic formulations

MECHANISM OF ACTION 

Chlormadinone works by activating progesterone receptors to produce progestogenic effects and blocking androgen receptors to reduce androgen activity. This dual action helps regulate the menstrual cycle, provide contraceptive effects, and treat androgen-dependent conditions like acne, hirsutism, and benign prostatic hyperplasia.

PHARMACOKINETICS

Absorption

Chlormadinone is well absorbed orally, with peak plasma concentrations typically reached within 1–2 hours after ingestion. Its bioavailability may be affected by liver metabolism, but it generally achieves sufficient systemic levels for therapeutic effects when taken as prescribed.

Distribution

Chlormadinone is highly protein-bound (96–98%) in the plasma and has a moderate volume of distribution (about 1–2 L/kg), allowing it to distribute effectively into body tissues while maintaining sustained therapeutic levels.

Metabolism

Chlormadinone is primarily metabolized in the liver through reduction, hydroxylation, and conjugation. Its metabolites are mostly inactive, and liver enzymes, particularly cytochrome P450 isoforms, play a key role in its biotransformation before excretion.

Excretion

Chlormadinone is well absorbed orally, reaching peak plasma levels within 1–2 hours. It is highly protein-bound (96–98%) and has a moderate volume of distribution (1–2 L/kg), allowing effective tissue distribution. The drug is primarily metabolized in the liver through reduction, hydroxylation, and conjugation, producing mostly inactive metabolites. Chlormadinone and its metabolites are excreted mainly in the urine (50–60%) and partly in feces, with an elimination half-life of approximately 25–34 hours, supporting once-daily dosing.

PHARMACODYNAMICS

1. Progestogenic activity: It binds to progesterone receptors, regulating the menstrual cycle, inhibiting ovulation, and providing contraceptive effects.

2. Anti-androgenic activity: It blocks androgen receptors, reducing the effects of testosterone and other androgens on target tissues, which helps treat androgen-dependent conditions like acne, hirsutism, and benign prostatic hyperplasia.

3. Endocrine modulation: By acting on the hypothalamic-pituitary-gonadal axis, it suppresses gonadotropin release, indirectly decreasing endogenous androgen production.

ADMINISTRATION

Administration is the process of managing and organizing the activities of an organization, institution, or government to achieve its goals effectively. It involves planning, decision-making, coordination, and supervision of resources and people. Good administration ensures smooth functioning, proper use of resources, and timely completion of tasks in areas like education, business, and public services.

DOSAGE AND STRENGTH

 Oral Contraceptive Use: Usually given in combination with an estrogen (e.g., ethinylestradiol) as a once-daily oral tablet. Typical dose: 2–5 mg of chlormadinone per day depending on the formulation.

• Treatment of Androgen-Dependent Conditions (e.g., hirsutism, acne): Often prescribed as 2–4 mg daily for several months, adjusted based on response.

• Benign Prostatic Hyperplasia (BPH) in Men: Administered at 50–100 mg per day, usually divided into one or two doses.

DRUG INTERACTIONS

• Enzyme Inducers: Drugs that induce cytochrome P450 enzymes (e.g., rifampicin, phenytoin, carbamazepine, phenobarbital, St. John’s Wort) may reduce plasma levels of chlormadinone, decreasing its efficacy.

• Other Hormonal Drugs: Co-administration with estrogens or other hormonal contraceptives may alter hormonal balance.

• Liver Metabolized Drugs: Drugs extensively metabolized by the liver may compete with chlormadinone, potentially altering its metabolism.

• Anticoagulants: Rarely, chlormadinone may affect the action of warfarin, requiring dose monitoring.

FOOD INTERACTIONS

Chlormadinone can be taken with or without food, as food does not significantly affect its absorption or efficacy. However, a high-fat meal may slightly delay the time to reach peak plasma concentration, but it does not alter overall bioavailability.

CONTRAINDICATIONS

Chlormadinone is contraindicated in pregnancy and lactation, as well as in patients with severe liver disease or liver tumors. It should not be used in individuals with hormone-sensitive cancers, such as breast cancer, or those with a history of thromboembolicevents, stroke, or severe cardiovascular disorders. Additionally, it is contraindicated in patients with hypersensitivity to chlormadinone or any component of the formulation.

SIDE EFFECTS

• Nausea and vomiting

• Headache or migraine

• Breast tenderness or enlargement

• Menstrual irregularities (spotting, breakthrough bleeding, or amenorrhea)

• Weight changes

• Fatigue or dizziness

• Mood changes (depression or irritability)

• Liver function abnormalities (rare)

• Allergic reactions (rash, itching, or swelling)

OVER DOSE

• Symptoms: nausea, vomiting, drowsiness, breast tenderness, menstrual irregularities

• Severe toxicity is rare

• No specific antidote; treatment is supportive and symptomatic

• Prognosis is generally favorable, but medical attention is recommended

TOXICITY

Chlormadinone has low toxicity, with overdose usually causing mild symptoms such as nausea, vomiting, drowsiness, breast tenderness, and menstrual irregularities. Long-term use may rarely affect liver function or lipid metabolism. It is contraindicated in pregnancy, and there is no specific antidote; treatment is supportive and symptomatic.